Immune checkpoint inhibitor-induced inflammatory arthritis
Fisher, Benjamin A Allard, Andrew Dubey, Shirish Mankia, Kulveer Pratt, Arthur G Pallan, Lalit
Fisher, Benjamin A
Allard, Andrew
Dubey, Shirish
Mankia, Kulveer
Pratt, Arthur G
Pallan, Lalit
Affiliation
University of Birmingham; University Hospitals Birmingham NHS Foundation Trust; Royal United Hospitals Bath NHS Foundation Trust; Oxford University Hospitals NHS Foundation Trust; University of Oxford; University of Leeds; Leeds Teaching Hospitals NHS Trust; Newcastle University; Newcastle Hospitals NHS Foundation Trust
Other Contributors
Publication date
2025-08-06
Subject
Collections
Research Projects
Organizational Units
Journal Issue
Abstract
Immune checkpoint inhibitors (ICI) used for the treatment of malignancy are associated with immune-related adverse events, which include inflammatory arthritis. ICI-induced inflammatory arthritis (ICI-IA) is a new clinical entity that may lead to functional impairment and may be persistent even after ICI cessation. We discuss the clinical features, investigation and differential diagnosis. Management needs to consider the safety of immunosuppression in the context of the underlying cancer, and current practice will be further informed by ongoing clinical trials.
Citation
Fisher BA, Allard A, Dubey S, Mankia K, Pratt AG, Pallan L. Immune checkpoint inhibitor-induced inflammatory arthritis. Clin Med (Lond). 2025 Sep;25(5):100496. doi: 10.1016/j.clinme.2025.100496. Epub 2025 Aug 6.
Type
Article